Product Approval Breathes New Life Into Boan Biotech IPO
The biosimilar drug maker was approved to sell its second new product in China last month as it applies to list in Hong KongKey Takeaways:Boan Biotechnology has filed for a…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
Discover hidden China stock gems in our weekly newsletter